Cargando…

Editorial: Transcriptional Regulation as a Key Player in Cancer Cells Drug Resistance

Detalles Bibliográficos
Autores principales:	Martinez-Balibrea, Eva, Ciribilli, Yari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576526/ https://www.ncbi.nlm.nih.gov/pubmed/34765559 http://dx.doi.org/10.3389/fonc.2021.764506

Ejemplares similares

Inflammation and Metabolism in Cancer Cell—Mitochondria Key Player
por: Neagu, Monica, et al.
Publicado: (2019)

Editorial: Altered epigenetic modification mediated dysregulated transcriptional networks in drug resistance
por: Brunetti, Bryce, et al.
Publicado: (2023)

Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance
por: Manzoor, Shaista, et al.
Publicado: (2022)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022)

Sphingolipids: Key Regulators of Apoptosis and Pivotal Players in Cancer Drug Resistance
por: Giussani, Paola, et al.
Publicado: (2014)

Myeloid-Derived Suppressor Cells as Key Players and Promising Therapy Targets in Prostate Cancer
por: Siemińska, Izabela, et al.
Publicado: (2022)

Key Players in Choline Metabolic Reprograming in Triple-Negative Breast Cancer
por: Iorio, Egidio, et al.
Publicado: (2016)

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
por: Qiu, Xia, et al.
Publicado: (2022)

Editorial: Drug-resistance in cancer cells: A new wine in an old bottle
por: da Fonseca, Leonardo Marques, et al.
Publicado: (2023)

Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma
por: Ciribilli, Yari, et al.
Publicado: (2017)

Correction: Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma
por: Ciribilli, Yari, et al.
Publicado: (2018)

Editorial: New insights into the mechanisms of resistance to anti-cancer drugs
por: Bertoni, Francesco, et al.
Publicado: (2022)

Current Management Strategies in Breast Cancer by Targeting Key Altered Molecular Players
por: Ali, Shazia, et al.
Publicado: (2016)

ETV7-Mediated DNAJC15 Repression Leads to Doxorubicin Resistance in Breast Cancer Cells()
por: Alessandrini, Federica, et al.
Publicado: (2018)

Sialic Acid Metabolism: A Key Player in Breast Cancer Metastasis Revealed by Metabolomics
por: Teoh, Shao Thing, et al.
Publicado: (2018)

Editorial: Impact of Cancer Plasticity on Drug Resistance and Treatment in Solid Tumors
por: Cohen, Pascale A., et al.
Publicado: (2020)

Editorial: Recent advances of drug resistance research in colorectal cancer therapy
por: Ye, Chenyang, et al.
Publicado: (2022)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Cuproptosis in ccRCC: key player in therapeutic and prognostic targets
por: Lv, Yang, et al.
Publicado: (2023)

Editorial: Targeting metabolism of cancer cells and host to overcome drug resistance: Preclinical and clinical studies
por: Wang, Lishun, et al.
Publicado: (2023)

Editorial: Heme proteins: key players in the regulation of immune responses
por: Volpi, Claudia, et al.
Publicado: (2023)

Epigenetic modifications: Key players in cancer heterogeneity and drug resistance
por: Sadida, Hana Q., et al.
Publicado: (2023)

c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma
por: Ciribilli, Yari, et al.
Publicado: (2016)

MYC as a Multifaceted Regulator of Tumor Microenvironment Leading to Metastasis
por: Meškytė, Erna Marija, et al.
Publicado: (2020)

Editorial: Hallmark of cancer: Resisting cell death
por: Zhu, Yichao, et al.
Publicado: (2022)

Editorial: Transcription Factors Drivers of Malignancy, Progression and Poor Outcomes in Breast Cancer
por: Parisi, Eva, et al.
Publicado: (2022)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
por: Yoon, Sungpil, et al.
Publicado: (2021)

Editorial: Overcoming drug relapse and therapy resistance in NSCLC
por: Parakh, Sagun, et al.
Publicado: (2023)

Editorial: Heparan Sulfate Proteoglycans and Their Endogenous Modifying Enzymes: Cancer Players, Biomarkers and Therapeutic Targets
por: Lanzi, Cinzia, et al.
Publicado: (2020)

Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells
por: Jin, Kaipeng, et al.
Publicado: (2023)

Editorial: Chemo-Resistance in Gastrointestinal Cancers
por: Li, Xia, et al.
Publicado: (2022)

MicroRNA-381—A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer
por: Zeng, Xue, et al.
Publicado: (2020)

Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas
por: Ciribilli, Yari, et al.
Publicado: (2015)

Editorial: Preclinical models and emerging technologies to study the effects of the tumor microenvironment on cancer heterogeneity and drug resistance
por: Adriani, Giulia, et al.
Publicado: (2023)

Editorial: Regulators of radiosensitivity in colorectal cancer
por: Bishnupuri, Kumar, et al.
Publicado: (2022)

ANXA6: a key molecular player in cancer progression and drug resistance
por: Cao, Jinlong, et al.
Publicado: (2023)

Editorial: Therapeutic drug monitoring and clinical toxicology of anti-cancer drugs
por: Liu, Yao, et al.
Publicado: (2022)

Editorial: Primary and acquired resistance in lung cancer
por: Bruno, Rossella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vrivsppd1jaheje0ib1g2f3cg8